The catecholamines dopamine (DA), norepinephrine (NE) and epinephrine (E) are neurotransmitters and hormones that mediate stress responses in tissues and plasma. The expression of b-amyloid precursor protein (APP) is responsive to stress and is high in tissues rich in catecholamines. We recently reported that APP is a ferroxidase, subsuming, in neurons and other cells, the iron-export activity that ceruloplasmin mediates in glia. Here we report that, like ceruloplasmin, APP also oxidizes synthetic amines and catecholamines catalytically (K m NE = 0.27 mM), through a site encompassing its ferroxidase motif and selectively inhibited by zinc. Accordingly, APP knockout mice have significantly higher levels of DA, NE and E in brain, plasma and select tissues. Consistent with this, these animals have increased resting heart rate and systolic blood pressure as well as suppressed prolactin and lymphocyte levels. These findings support a role for APP in extracellular catecholaminergic clearance.
Introduction
Catecholamines mediate regulatory physiology in both the peripheral and central nervous systems. As neurotransmitters and hormones, they arbitrate an intrinsic alert and stress response, increasing heart rate, blood pressure and gluconeogenesis. 1 Catecholamines also induce the liberation of free fatty acids from adipose tissue, and the secretion of hormones. [2] [3] [4] [5] Sustained elevation of catecholamines suppresses the proliferation and survival of lymphocytes directly, 6 and indirectly by lowering prolactin levels. 7 Stored in specialized cellular vesicles until required, the catecholamines dopamine (DA) and norepinephrine (NE) predominantly act as neurotransmitters within the brain, whereas NE and another catecholamine derived from DA, epinephrine (E), are the major peripheral catecholamines synthesized in the medulla of the adrenal gland. 8 Endogenous production of catecholamines has also been found in the heart, 9, 10 immunocompetent cells, 6 gut 11 and kidneys. 12, 13 Upon release of catecholamines during neurotransmission in the brain, mechanisms around the synapse clear 80-90% of the neurotransmitter, but spillover of excess catecholamines may act on targets at a distance and enter plasma.
14 Perisynaptic catecholamine concentrations of 30-400 mM are estimated 14, 15 but drop to nM levels in the plasma 14 due to diffusion, transporter uptake and enzymatic breakdown. 15, 16 Following uptake, catecholamines are transported into vesicles or degraded by multiple intracellular pathways including methylation (for example catechol-Omethyltransferase) and amine oxidation. 1, 17 Deamination mainly occurs through the flavin adenine dinucleotide-dependent D-amino acid oxidase/sarcosine oxidase family and the monoamine oxidase family. 18 However, other amine oxidase activities not within these enzyme families have also been reported.
Ceruloplasmin (CP) is expressed as a soluble form in extracellular fluid and a GPI-anchored protein on the cell surface of select cells. [19] [20] [21] It has broad oxidase activity towards substituted organic compounds 22 as well as iron 23 and nitric oxide. 24 Although CP ferroxidase activity has been heavily investigated, less data exist on its role as an amine oxidase. However, the oxidation of synthetic substrates 23 as well as physiologically important substrates such as DA, NE and E are all catalyzed by CP. [25] [26] [27] Neurons do not express CP, but instead, we recently found, depend on amyloid precursor protein (APP) for iron-export ferroxidase activity. 28 APP is a transmembrane protein expressed in most tissues. It is processed into fragments that include the soluble APP species found within plasma. 29 As CP is also an amine oxidase, we reasoned that if APP replaces the functions of CP in certain cells, it might also be an amine oxidase with the ability to decrease catecholamine levels by catalytic degradation.
Materials and methods

Reagents
Reagents were all analytical grade and were purchased from Sigma (St Louis, MO, USA), unless otherwise specified. Purified human ceruloplasmin was purchased from Vital Products (Boynton Beach, FL, USA).
Mice
All mouse studies were performed with the approval of the IACUC and in accordance with statutory regulations. APP-knockout mice 30 and background controls (C57BL6/SV129) were thoracotomized under deep anesthesia, and heparinized blood was obtained from the left atrium. Plasma was separated immediately from red blood cells when required by centrifugation at 4000 Â g for 10 min. Tissues were then taken and either used immediately or stored at À80 1C until required.
Recombinant protein production and purification
The recombinant fragments of the human soluble APP695a, human APLP2 ectodomain and APP-E1 (amino acids 28-189) and APP-growth factor domain (amino acids 28-123) were expressed in the methylotrophic yeast Pichia pastoris strain GS115 and purified as previously described. 31, 32 APP-E2 (amino acids 290-495) was amplified in the E. coli BL21(DE3). Following induction by isopropyl b-D-1-thiogalactopyranoside the bacterial cells were collected by centrifugation for subsequent protein purification.
All fragments required a two-step procedure performed using an AKTA FPLC (GE Healthcare, Milwaukee, WI, USA). APP695a and APP-E1 was purified from culture media as previously described 31 using anion exchange on a Q-Sepharose column (1.6 Â 25 cm column, GE Healthcare) followed by hydrophobic exchange with phenyl-Sepharose (0.5 Â 5 cm column, GE Healthcare). APP-E2 and APP-growth factor domain purification was achieved by heparin chromatography using heparin-Sepharose (1.6 Â 12 cm; GE Healthcare) and anion exchange on Q-Sepharose (1.6 Â 25 cm column, GE Healthcare). 33 O-dianisidine oxidase activity assay The assay was based upon published procedures and standardized to international enzyme units (U l À1 ) as described. 34 Briefly, samples were incubated at 37 1C after being mixed with either 75 mM sodium acetate buffer pH 5.0 or 50 mM HEPES, pH 7.2 in 150 mM NaCl. O-dianisidine dihydrochloride substrate (7.88 mM) was added (1.576 mM final concentration), mixed and then incubated for 5 and 60 min. Sulfuric acid (9 M) was used to stop the reaction at these times. Oxidized product was monitored by absorbance at 540 nm from where the velocity was plotted. When not specified, 500 nM of pure protein or 5 ml plasma was used to measure oxidase activity. Sodium azide (10 mM) abolished the activity of pure ceruloplasmin, and zinc (10 mM) abolished the activity of pure APP695a in the assay.
p-Phenylenediamine (PPD) oxidase activity assay Based upon published methods, 35, 36 samples were incubated with 0.01% PPD substrate in acetate buffer, pH 5.45, for 30 min at 37 1C in the dark. Color development was monitored as absorbance at 570 nm.
Fluorometric detection of catecholamines
Varying concentrations of NE and DA were added to 50 nM APP695a in acetate buffer, pH 5.5. In total volume of 200 ml samples were shaken (220 rpm) for 1 h at 37 1C in the dark. Free amines were detected with fluorescamine (5 mM) at 390 nm excitation and 465 nm emission with a 455-nm cutoff. Oxidized substrate was calculated by subtracting the residual unmodified amines detected in this assay from the total added as a substrate. To control for autooxidation by NE and DA, samples incubated with APP were subtracted from the average absorbance of control samples that contained substrate oxidation without APP. NE and DA concentrations were determined by plotting against a standard curve.
High-pressure liquid chromatography with electrochemical detection of catecholamines Tissue or plasma was homogenized by pulse sonication in 0.4 M perchloric acid, 0.15% sodium metabisulfite and 0.05% EDTA before centrifugation at 13 000 rpm at 4 1C for 10 min. Homogenized tissue supernatants or plasma (50 ml) were injected onto a MD-150 reverse phase C18 column (ESA Biosciences, Sunnyvale, CA, USA) using a HPLC system (ESA Biosciences; model 584) coupled to an electrochemical detector (ESA Biosciences; Coulochem III detector) (E1:À150 mV, E2: þ 220 mV and guard cell: þ 250 mV). Peaks were identified by retention times set to known standards in mobile phase (75 mM sodium dihydrogen phosphate, 1.7 mM 1-octanesulfonic acid sodium salt, 100 ml l À1 triethylamine, 25 mM EDTA, 10% acetonitrile, pH 3) at a flow rate of 0.6 ml min À1 . Data were normalized for total wet weight of sample.
Histological detection of catecholamines Fluorescent detection of catecholamines was achieved by treatment of 10 mm cryostat tissue sections with an aqueous mixture of 4% formaldehyde and 0.5% glutaraldehyde (FAGLU), as previously described. 37 Dopamine toxicity measurement by cell viability assays Mouse embryonic fibroblasts (MEFs) were prepared from individual embryos omitting the head, liver and gastrointestinal organs. A cell suspension was generated by gently shaking for 20 min at 37 1C in 0.25% w/v trypsin followed by passage through an 18-gauge syringe and then triturated using a Pasteur pipette in a trypsin inhibitor mix (0.01% w/v lima bean trypsin inhibitor (LBTI) and 0.003% w/v Dnase). The pelleted cell suspension was suspended in Dulbecco's minimal Eagle's medium (Life Technologies, Grand Island, NY, USA) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 100 U ml À1 penicillin G, 100 mg ml À1 streptomycin and 10% fetal calf serum, and incubated at 37 1C with 5% CO 2 supplement. Fresh Dulbecco's minimal Eagle's medium was added after 24 h growth in a plate and then changed every 3-4 days thereafter. After 7-10 days incubation, MEFs were seeded on a 48-well plate and allowed to incubate in culture for 2-3 days before commencement of experiments. On the day of DA toxicity experiments, medium was replaced with fresh OPTIMEM (Life Technologies, Grand Island, NY, USA) without fetal calf serum and varying concentrations of DA (prepared immediately before addition to media). The cells were treated for 24 h after which media was removed and fresh OPTIMEM containing 10% v/v CCK-8 (Dojindo Molecular Technologies, Rockville, MD, USA) was added. After a further 2 h incubation at 37 1C, the absorbance of the media was read at 460 nm, which is proportional to viability.
Physiological testing
Systolic blood pressure and heart rate were determined non-invasively by tail-cuff plethysmography (Hatteras Instruments, MC4000 Blood Pressure Analysis System, Cary, NC, USA). Briefly, the tail-cuff method required mild restraint of the mouse in a dark chamber on a heated platform with their tails threaded through a tail cuff. Following a period of training (3 days), readings of blood pressure from the tail were then taken by brief cuff inflation (B5-10 s). This procedure was repeated 2-3 times for each mouse.
Prolactin assay
Prolactin from plasma (50 ml, in triplicate) was assayed using a commercially available kit (R&D systems, Minneapolis, MN, USA) and following the manufacturer's recommended procedure.
Lymphocytes count in blood
Blood was collected in lithium heparin tubes. Complete blood counts were analyzed within 1 h of collection using the Advia 120 hematology analyzer (Bayer Diagnostics, Tarrytown, NY, USA). All analytes were measured from complete blood counts and the percentage of lymphocytes were automatically calculated through the manufacture's software using the formula; ((100 Â lymphocyte count)/PHA cells)-% of basophils.
Results
APP oxidizes o-dianisidine dihydrochloride and PPD
The aromatic amine oxidase activity of CP has been extensively characterized with the synthetic substrates o-dianisidine dihydrochloride and PPD. 34, 35 We found that APP695a possesses oxidase activity similar to CP with these substrates, with Km values for o-dianisidine (0.55 mM at pH 7.2, and 0.21 mM at pH 5) and PPD (0.24 mM at pH 5.5) very similar to those we observed for CP (Figure 1a-c) , and previously reported for CP. 34 APP695a exhibits near-maximal o-dianisidine oxidase activity through a pH range of 4.5-7.5, with maxima at pH 5.0 and 7.0 (Supplementary Figure S1) , which is different to its pH optima for ferroxidase activity, 28 indicating that the amine oxidase active site on APP may not be identical to the ferroxidase domain. We mapped the amine oxidase site of APP to within the APP E2 domain (Figure 1d and e) and dependent on the intact ferroxidase domain as a mutation within the consensus REXXE ferroxidase motif-abolished activity (FD1 E415N -APP, Figure 1e ). However, the ferroxidase domain peptide alone, which retains ferroxidase activity, 28 did not oxidize o-dianisidine (FD1, Figure  1e ). By analogy, the ferroxidase and amine oxidase activities of CP are also overlapping but not identical. 38 Isolated soluble APPa isoforms 695, 751 and 770 had similar oxidase activity (Supplementary Figure S2) , however the APP-E2 domain had E60% the activity of APP695a (Figure 1e ), proportional to its ferroxidase activity. 28 Although purified APP-E1 domain (Figure 1d and e) possessed no oxidase activity, equimolar concentrations of APP-E1 almost doubled APP-E2 activity (Figure 1f) to that of APP695a (Figure 1e ). We mapped this potentiating effect to the growth factor domain (Figure 1d and e) within APP-E1, which has a similar potentiating effect on the ferroxidase activity of APP-E2. 28 The oxidase activity of CP was inhibited by azide (Figures 2a and b) as expected, 25 but, as with APP695a ferroxidase activity, 28 azide did not inhibit amine oxidase activity (Figure 2a) . However, Zn 2 þ inhibited APP695a ferroxidase activity, 28 and also saturably inhibited APP695a amine oxidase activity (Ki = 0.759 mM, Figure 2a and b) . Although the amine oxidase activity of APP-E2 was diminished compared with APP695a, it similarly was inhibited by Zn 2 þ (Figure 2b ) but not by azide or physiological concentrations of other divalent metal ions, for example, 20 mM Cu 2 þ . As with ferroxidase activity, 28 APLP2 did not possess amine oxidase activity (Figure 2a) , presumably due to it not possessing the ferroxidase domain essential for amine oxidase activity ( Figure  1e ). The selective inhibitors to monoamine oxidases A (clorgyline) and B (selegiline) had no effect on the activities of either APP695a or CP (Figure 2a) .
Decreased o-dianisidine dihydrochloride oxidation in APP knockout plasma O-dianisidine oxidation is used in clinical pathology as an assay for plasma CP activity. 34 We mapped the components that oxidize this amine substrate by assaying plasmas from CP knockout (CPÀ/À), APP knockout (APPÀ/À) as well as age-and gendermatched background control mice. Both azide and genetic ablation of CP induced a E60% drop in plasma amine oxidase activity (Figure 2c -e) and the remaining oxidase activity in the CPÀ/À plasma could not be inhibited by azide (Figure 2d ). By comparison, genetic ablation of APP caused a E40% decrease in plasma oxidase activity with the residual activity completely inhibited by azide (Figure 2e ), consistent with it being due to CP. Zn 2 þ inhibited the same proportion of amine oxidase activity in wild-type plasma as the activity lost in APPÀ/À plasma (Figure 2c ). The loss of either oxidase activity in each type of knockout mouse was not associated with increased expression of an alternative amine oxidase, indicating that the activities are not redundant (Figure 2d and e) .
APP catalyzes the oxidation of catecholamines
The physiological relevance of amine oxidation by APP695a was examined for catecholamines. NE, E and DA were found to competitively inhibit the oxidation of o-dianisidine by APP in a dose-dependent manner (Figure 3a) . Each catecholamine completely inhibited o-dianisidine oxidation at 1:1 stoichiometry (Figure 3a) .
The catalytic oxidation of NE and DA by APP was confirmed by a fluorometric assay of exposed primary amine groups that precluded the assay of E (Figure 3b ). NE and DA were oxidized by APP695a with similar K m values. Although oxidation was not as proficient as the synthetic substrates (Figure 1c ) it was comparable to activities previously reported for CP. 39 
APP depletion increases DA toxicity in cells
We hypothesized that the oxidase activity of endogenous APP may have a protective effect on the cell against DA toxicity. Consistent with APP oxidase activity being able to safely metabolize catecholamines, the LD50 for DA administered to the media of Figure 2 Inhibitors of oxidase activities differentiate APP from other known oxidases in plasma. (a) The effects of azide (10 mM), Zn 2 þ (10 mM) and the monoamine oxidase inhibitors clorgyline (MAO-A specific) and selegiline (MAO-B specific) upon o-dianisidine oxidation by 500 nM CP, APP695a and APLP2. As previously reported, CP was inhibited by azide 69 whereas APP695a was inhibited by Zn 2þ . 28 Neither were inhibited by MAO inhibitors and APLP2 had no oxidase activity. (b) Inhibition curves of o-dianisidine oxidase activities of CP (by azide), APP695a and APP-E2 (by Zn 2 þ ). Inhibition is saturable with similar K i values between APP695a and APP-E2. (c) O-dianisidine oxidase activity of wild-type mouse plasma inhibited by azide (10 mM) leaves a residual activity similar to total activity in APPÀ/À mice (e). Alternatively, plasma after Zn 2 þ (10 mM) inhibition possesses B50% of the total activity and is proposed to represent total multi-copper oxidase activity. The sum of oxidase activities after azide or Zn 2 þ inhibition is equal to the total. (d) O-dianisidine oxidase activity of plasma from CPÀ/À mice is markedly decreased compared with background control mice, but is not inhibited by azide (consistent with APP azide resistance). (e) O-dianisidine oxidase activity of APPÀ/À plasma is markedly decreased compared with background control mice, and is completely inhibited by azide (consistent with the residual activity present in APPÀ/À mice being CP). All o-dianisidine assays were performed in 75 mM Na Acetate, pH 5.0, 37 1C. Oxidase activity were performed at pH 5.0 and calculated in Ul À1 as previously described. 34, 35 Data are means ± s.e.m., n = 3. mouse embryonic fibroblasts (MEFs) was twofold higher in cultures from wild type (510 mM) compared with those from APPÀ/À mice (226 mM, Figure 3c ).
Increased catecholamines in APP knockout mice
High APP levels are found in brain stem neurons, 40 the medullae chromaffin cells of the adrenal gland, 41 the heart, 28 and soluble APP is present in plasma. 29 We assayed catecholamine levels in these tissues, which are important for the sympathetic nervous system. Where detectable, levels of catecholamines in these tissues were markedly higher in APPÀ/À mice (NE (Figure 4a ), E ( Figure 4b ) and DA (Figure 4c) ) than age-matched background controls (concentrations are reported in Figure 4d ). The increased catecholamine levels could be visualized histologically within these tissues (Figure 4e ). Plasma from APPÀ/À mice also carried significantly higher concentrations of the three catecholamines (Figure 4a-d) , in accordance with the decreased oxidase activity observed within the plasma of these mice (Figure 2e ).
Chronic rise in catecholamines lead to altered physiology in APP knockout mice The body's response to stress is an increased presence of NE and E, leading to elevated heart rate and blood pressure. 1 APPÀ/À mice exhibited increased heart rate ( Figure 5a ) and systolic blood pressure (Figure 5b ) consistent with the increased NE and E present in the heart and plasma (Figure 4a,b and d) . We also tested for the impact of elevated brain DA levels on the tuberoinfundibular-dopaminergic system by assaying prolactin, a pituitary hormone whose release is suppressed by the presence of DA. Indeed plasma prolactin levels were significantly decreased in APPÀ/À mice (Figure 5c ), consistent with increased brain stem DA in these mice (Figure 4c and d) . Prolactin is a hormone implicated in immunomodulation, 42 and accordingly the lymphocyte count of APPÀ/À mice was significantly decreased compared with wild type (Figure 5d ).
Discussion
Here we have characterized a catalytic catecholamine oxidation by APP that is not diminished by monoamine oxidase inhibitors (Figure 2a) . 18 A motif was found within the ectodomain of APP that mediates the oxidation of synthetic amines (Figure 1 ) as well as catecholamines ( Figure 3 ) and genetic ablation of APP in mice elevated DA, NE and E levels. Indeed, the degree of catecholaminergic accumulation in APPÀ/À mice ( Figure 4 ) is similar to monoamine oxidasedeficient mice (for example, MAO-A). 43 The location of APP throughout the body as well as within the cell appears to fit well with the distribution of catecholamines upon release. Catecholamine production is most pronounced in chromaffin cells of the adrenal medulla and within brain stem neurons; cell types with the highest expression of APP695 within the body. 40, 41 In tissue, full-length APP is responsive to stress 44 and the active site is on the extracellular surface of the plasma membrane (Figure 1d ). Unlike CP, 28 APP is expressed in all neurons, at synaptic junctions, 45, 46 which may make it available for controlling catecholamine concentrations in the vicinity and modulated by extracellular Zn 2 þ concentrations transferring from nearby synapses. 47 The K m of APP is also suitable for the spillover of concentrations of catecholamines that are not cleared by uptake transporters. In addition, full-length APP has been identified on the mitochondrial membrane, 48 where monoamine oxidase A and B are also predominantly expressed 49 and soluble APP is within the plasma, which transports DA, NE and E for peripheral activities.
NE, E and to some extent DA directly orchestrate heart rate and blood pressure. 1 Without deamination of catecholamines at sites of action within the tissue, sustained chronic increases can lead to detrimental consequences, for example, hypertension. APPÀ/À mice showed a significant increase in both heart rate and systolic blood pressure (Figure 5a and b) corresponding to the increased NE and E present within heart tissue as well as plasma (Figure 4a and b). Similar events have been observed with the inhibition 50 or genetic ablation 51 of other catecholamine oxidases.
Consistent with increased DA within the brain stem of APPÀ/À mice (Figure 4c ), prolactin secretion into Figure 4 APP-deficient mice have increased catecholamines. High-performance liquid chromatography with electrochemical detection revealed increased norepinephrine (a), epinephrine (b) and dopamine (c), here represented as a percentage relative to wild-type age-matched controls, in tissues of relevance to the sympathetic nervous system as well as plasma. (d) Specific catecholamine concentrations within each biological sample calculated using a standard curve for each catecholamine. (e) Localized catecholamine levels in the medullae (M) and cortex (C) of the adrenal gland, neurons of the locus ceruleus (LC) and lateral dorsal tegmental (LDTg) regions of the brain stem as well as the endocardium (En), myocardium (My) and epicardium (Ep) of the heart were visualized by FAGLU histology. Scale bars are 200 m for the adrenal gland and heart, 50 m for brain stem. Data are means±s.e.m. of (a-d) n = 5 & (e) n = 3. * = P < 0.05, **P < 0.01, ***P < 0.001 analyzed by two-tailed t-tests. plasma decreased (Figure 5c ). Prolactin has multiple effects upon growth, metabolism and immunomodulation, as well as reproduction, for which it is best characterized. 52 Evidence provided here and previously shows phenotypic abnormalities in APPÀ/À mice that can be related to the significant reduction in prolactin release caused by increased DA in the brain stem. Decreased prolactin could explain the 15-20% reduction in adult body weight seen in APPÀ/À mice, 30 as prolactin suppression results in decreased food intake and body weight. [53] [54] [55] Plasma glucose is also decreased in APPÀ/À mice. 56 Although this may be due to increased metabolism resulting from chronically elevated catecholamines, 57 prolactin suppression also elevates adipokines (for example, adiponectin 58 ) causing decreased plasma glucose. 59, 60 Prolactin, acting as a cytokine, additionally promotes the proliferation and survival of lymphocytes. 42, 61 This may contribute to the decreased lymphocyte count in APPÀ/À mice (Figure 5d ), as may elevated catecholamines directly impairing lymphocyte survival. 1 Evidence indicates that APP amine oxidase activity may be pathologically increased in Down's syndrome, where there is a trisomy of chromosome 21 (that carries APP). These patients have reduced brain catecholamine levels, 62 with blunted sympathetic response and heart rate. 63 Similarly, cognitive defects in a Down's syndrome mouse model are partly caused by adrenergic deficiency, 64 and elevating NE levels can partially restore this deficit. 65 Down's patients also have elevated prolactin, 66 consistent with decreased DA in the pituitary hypophysis. The inhibition of APP activity by zinc may also be a reason as to why zinc supplementation has provided several benefits to individuals with Down's syndrome. 67 Our data indicate that APP is a significant factor in the clearance of catecholamine. It is notable that both APP and CP possess concomitant ferroxidase and amine oxidase activities. Although the kinetics of these activities are strikingly similar for both proteins (Figure 1c) , 28 they are mediated by protein domains that are not structurally homologous and by different electrochemical reaction mechanisms. CP activity depends on copper, whereas APP activity does not. Therefore, the similarities in activities are unlikely to be coincidental, and we hypothesize that they have evolved to meet a similar physiological need in differing chemical environments. Pairing ferroxidation with amine oxidation may be a means of preventing the oxidation of catecholamines by Fe 3 þ into toxic products, 68 which may be important at sites of high catecholamine levels such as the synapse, or at sites of high iron concentration such as the blood. Amine oxidase activity would also facilitate the loading of Fe 3 þ onto transferrin by preventing Fe 3 þ reduction by catecholamines or other bioamines. The modulation of catecholamine levels in the brain and sympathetic target organs is an important end effect for several major classes of psychotropic and cardiovascular drugs. The discovery that APP has an adjustable activity that influences catecholamine levels at these sites has important implications for clinical pharmacology.
Conflict of interest
AIB, DIF and KJB are shareholders and paid consultants for Prana Biotechnology. AIB is a shareholder in Brighton Biotech, and paid consultant for Adeona. JAD and AIB have received speaking honoraria from The percentage of lymphocytes as a proportion of white cell count was reduced in APPÀ/À mice. Total white cell count was not significantly altered. Data are means ± s.e.m., n = 5. *P < 0.05, **P < 0.01, ***P < 0.001, analyzed by two-tailed t-tests.
Amgen. The remaining authors declare no conflict of interest.
